



IBA releases the 3rd version of myQA® connecting Relative Dosimetry to the Global QA Platform

Commissioning data on the myQA Platform allows beam scans to be used as individual references for machine QA.

Schwarzenbruck, Germany, February 04, 2016 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the third release of the global quality assurance platform: **myQA®**. myQA is a unique platform that connects QA applications and data through a central database and software application. With this new release, **Relative Dosimetry** is now connected to myQA® along with the already released **Machine QA** and **Patient QA**. One key innovation is that hospitals can now benchmark their individual data compared to other gold standard scans to ensure high confidence in Linac commissioning and QA accuracy.

*“myQA is recognized as the first global QA platform and is also the only QA platform that connects all major dosimetry applications Machine QA as well as Patient QA under one consistent roof! Customers can now also link **myQA Accept** commissioning and annual QA software to their myQA platform,” says **Salih Arican, Senior Product Manager Relative Dosimetry at IBA Dosimetry**. “This latest release is yet another milestone for our users in extending the frontiers in highly efficient and effective QA workflows.”*

myQA Cloud, also part of the newly released software, offers users the unique opportunity to anonymously benchmark their scan data and connect with users from around the world. This online tool not only contributes to best practice checks, but also gives its users full trust in their scan results. myQA Cloud does not compute any data on the cloud, so users keep full control of their data!

*“IBA is proud to announce the release of the third version of myQA in only nine months since the initial launch of the QA Platform. Our goal is to continuously advance and upgrade myQA to the needs and demands of the market to ensure our users have the most cutting edge solution out there”, says **Ralf Schira, Vice President Marketing at IBA Dosimetry**. “Through the **myQA Coverage** package, IBA ensures that our users always directly benefit from each new release of myQA. Other unique benefits of myQA Coverage include the new 24/7 hotline and Support Portal that connects our customers directly with professionally trained IBA service staff.”*

[Learn more about myQA here.](#)

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA

Press Release |




also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe to the United States, and to the emerging markets. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Media Contact:

Jacqueline McMahon
IBA Dosimetry GmbH
Bahnhofstr. 5
90592 Schwarzenbruck, Germany
Tel: +49 9128 607 0
jacqueline.mcmahon@iba-group.com
www.iba-dosimetry.com



myQA Accept now connected to the **myQA®** global QA platform